about
TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitroRole of the vaginal microbiological ecosystem and cytokine profile in the promotion of cervical dysplasia: a case-control studyGab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cellsPhase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancerTRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.Gynecologic biopsy for molecular profiling: a review for the interventional radiologistRisk-reducing salpingectomy as preventative strategy for pelvic serous cancer.Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents.Social and cultural barriers to Papanicolaou test screening in an urban population.Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model.Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival.All-trans-retinoic acid inhibits the proliferation of cell lines derived from human cervical neoplasia.Novel TP53 gene mutation and correlation with p53 immunohistochemistry in a mixed epithelial carcinoma of the endometrium.Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma.Racial differences in survival from gynecologic cancer.Outcomes of women with atypical glandular cells on preoperative cytology and endometrial cancer.Allelotype analysis of uterine leiomyoma: localization of a potential tumor suppressor gene to a 4-cM region of chromosome 7q.Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations ofBRCA1A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group sPrognostic indicators of survival in advanced endometrial cancerBRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testingAdenosarcoma in a patient with vaginal endometriosisClinical characteristics of clear cell carcinoma of the ovaryTotal pelvic exenteration with a split-thickness skin graft neovagina, continent orthotopic neobladder and rectal reanastomosis, resulting in no external ostomies and adequate sexual functionSurgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancerActivation of Wnt signaling promotes olaparib resistant ovarian cancer
P50
Q33802751-DB4D35CB-87C7-4FE2-9EDC-A9CE68BA4BFCQ35614701-A144FCFD-14F4-483B-B607-CBC4C7F214FAQ35683214-C554DA72-362C-4414-9867-5A837C41515EQ35913613-CE47F30F-98EF-4DB7-B2C4-D62095636E97Q36714078-D0369C83-148C-4CEE-AECC-A90CF4F14520Q36731174-9857C8CF-57C9-4A81-ACCD-FEF8FEBCAFADQ37329840-DD847776-0914-4A1B-96C0-EE168E79EE29Q38079398-E90B5D26-201A-4DD6-B84E-923E9D5B9CDFQ39583729-7A4166C9-EF20-4C19-80EF-A06596B99C7AQ39701785-9CF3460D-D6CB-41DE-981B-1A8AD2F9458BQ39962489-23C336D3-99DC-46EE-A334-21F1DA384504Q40149403-DDC1998A-EDA9-4A2D-9034-0842431A851DQ41211020-B9C33EC6-C2B2-4CA2-B5A6-970EB1AA2A5CQ42796769-2ABA9644-578F-436B-B6AC-4A7E151AE7EDQ44373686-A3C92A73-6A62-4294-A6B3-4928D66ABDC5Q53003926-8AE034C8-7FD9-48B7-A68B-6C64BBFBD10AQ53074053-B723F0E4-769D-4149-8306-9D6850F59932Q54430928-9C9B81F3-48A7-4D76-ACE4-C54FE09F9508Q63183299-9C56B823-4ED9-4EFA-9B6B-553E378E3327Q64110569-81B43ED0-129F-4922-8AC5-120A37D437D0Q72461987-4DD379F1-78D3-41F4-80A7-908FCA5F8DA4Q74525381-8FE4A6BA-2E31-4DBF-ADDE-18E682EA5EADQ77157164-60012EF1-0073-4CD2-ACDC-F83D68293D84Q77310523-30E152A0-489B-443A-BD33-5A03014229CBQ84373240-94A27919-A177-4CA9-B463-CA8DDF3A4FCEQ85091613-A5DD9C2C-994C-4F8E-B44E-3EE1F5CDBFCCQ92898302-E9CDC686-9ECF-44DF-B2AC-DE7289112671
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kian Behbakht
@ast
Kian Behbakht
@en
Kian Behbakht
@es
Kian Behbakht
@nl
Kian Behbakht
@sl
type
label
Kian Behbakht
@ast
Kian Behbakht
@en
Kian Behbakht
@es
Kian Behbakht
@nl
Kian Behbakht
@sl
prefLabel
Kian Behbakht
@ast
Kian Behbakht
@en
Kian Behbakht
@es
Kian Behbakht
@nl
Kian Behbakht
@sl
P106
P1153
6602166990
P31
P496
0000-0003-4793-9958